Irsamla (Vortioxetine)

Vortioxetine acts as a multimodal serotonin agent. It agonises 5‑HT1A receptors, partially agonises 5‑HT1B, antagonises 5‑HT3 and 5‑HT7 receptors, and blocks the serotonin transporter, leading to increased serotonin availability and balanced neurotransmission, which contributes to its antidepressant and pro‑cognitive effects.

The dosage of Irsamla is determined individually by a qualified prescriber based on the patient’s clinical condition, response and tolerability. The prescribing physician will select the appropriate strength and titration schedule in accordance with local prescribing guidelines.

Safety of vortioxetine during pregnancy or lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the Irsamla product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative in the same class is selective serotonin reuptake inhibitors such as escitalopram. Unlike pure SSRIs, vortioxetine has additional receptor activity that may offer benefits in cognition and lower rates of certain side effects, though individual response varies and choice should be guided by the prescriber.

Irsamla tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container, protected from moisture and direct sunlight. Keep the medication out of reach of children and do not use after the expiry date printed on the packaging.

Irsamla is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with water and not crushed or chewed, unless otherwise instructed by a healthcare professional.

Patients should be alert for signs of serotonin syndrome, such as agitation, rapid heart rate, high blood pressure, dilated pupils, loss of muscle coordination or sweating. Also monitor for emergent suicidal thoughts, severe hyponatremia, allergic reactions, and any unusual bleeding, and seek immediate medical attention if these occur.

Irsamla is contraindicated in individuals who are currently taking monoamine oxidase inhibitors, have known hypersensitivity to vortioxetine, or have a history of severe serotonin syndrome. Caution is advised in patients with hepatic impairment, uncontrolled hypertension, or those using other serotonergic medications, and the drug should be avoided in such cases unless specifically directed by a physician.